Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5700775 | European Journal of Surgical Oncology (EJSO) | 2017 | 6 Pages |
Abstract
DCIS may be completely eradicated by NAC ± trastuzumab. However, associated microcalcifications probably persist. Patients with locally advanced breast cancer with substantial DCIS may still opt for NAC and breast conservation as the DCIS component may respond and even completely disappear following NAC. Residual widespread microcalcifications after NAC do not necessarily indicate residual cancer. Larger studies are needed to direct the surgical management of these patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
H. Goldberg, J. Zandbank, V. Kent, M. Leonov-Polak, A. Livoff, A. Chernihovsky, M. Guindy, E. Evron,